Literature DB >> 31269444

Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection.

Konrad C Bradley1, Katja Finsterbusch1, Daniel Schnepf2, Stefania Crotta1, Miriam Llorian3, Sophia Davidson1, Serge Y Fuchs4, Peter Staeheli5, Andreas Wack6.   

Abstract

Type I interferon (IFNα/β) pathways are fine-tuned to elicit antiviral protection while minimizing immunopathology; however, the initiating stimuli, target tissues, and underlying mechanisms are unclear. Using models of physiological and dysregulated IFNα/β receptor (IFNAR1) surface expression, we show here that IFNAR1-dependent signals set the steady-state IFN signature in both hematopoietic and stromal cells. Increased IFNAR1 levels promote a lung environment refractory to early influenza virus replication by elevating the baseline interferon signature. Commensal microbiota drive the IFN signature specifically in lung stroma, as shown by antibiotic treatment and fecal transplantation. Bone marrow chimera experiments identify lung stromal cells as crucially important for early antiviral immunity and stroma-immune cell interaction for late antiviral resistance. We propose that the microbiota-driven interferon signature in lung epithelia impedes early virus replication and that IFNAR1 surface levels fine-tune this signature. Our findings highlight the interplay between bacterial and viral exposure, with important implications for antibiotic use.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anti-viral protection; antibiotics; gut; influenza; lung; microbiota; tonic IFN signaling; type I interferon (IFN)

Mesh:

Substances:

Year:  2019        PMID: 31269444     DOI: 10.1016/j.celrep.2019.05.105

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  88 in total

1.  The Intestinal Microbiome Restricts Alphavirus Infection and Dissemination through a Bile Acid-Type I IFN Signaling Axis.

Authors:  Emma S Winkler; Swathi Shrihari; Barry L Hykes; Scott A Handley; Prabhakar S Andhey; Yan-Jang S Huang; Amanda Swain; Lindsay Droit; Kranthi K Chebrolu; Matthias Mack; Dana L Vanlandingham; Larissa B Thackray; Marina Cella; Marco Colonna; Maxim N Artyomov; Thaddeus S Stappenbeck; Michael S Diamond
Journal:  Cell       Date:  2020-07-14       Impact factor: 41.582

2.  The commensal skin microbiota triggers type I IFN-dependent innate repair responses in injured skin.

Authors:  Jeremy Di Domizio; Cyrine Belkhodja; Pauline Chenuet; Anissa Fries; Timothy Murray; Paula Marcos Mondéjar; Olivier Demaria; Curdin Conrad; Bernhard Homey; Sabine Werner; Daniel E Speiser; Bernhard Ryffel; Michel Gilliet
Journal:  Nat Immunol       Date:  2020-07-13       Impact factor: 25.606

Review 3.  Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.

Authors:  S F Yanuck; J Pizzorno; H Messier; K N Fitzgerald
Journal:  Integr Med (Encinitas)       Date:  2020

4.  Gamma-glutamyltransferase of Helicobacter pylori alters the proliferation, migration, and pluripotency of mesenchymal stem cells by affecting metabolism and methylation status.

Authors:  Zeyu Wang; Weijun Wang; Huiying Shi; Lingjun Meng; Xin Jiang; Suya Pang; Mengke Fan; Rong Lin
Journal:  J Microbiol       Date:  2022-04-18       Impact factor: 3.422

5.  Homeostatic interferon-lambda response to bacterial microbiota stimulates preemptive antiviral defense within discrete pockets of intestinal epithelium.

Authors:  Jacob A Van Winkle; Stefan T Peterson; Elizabeth A Kennedy; Michael J Wheadon; Harshad Ingle; Chandni Desai; Rachel Rodgers; David A Constant; Austin P Wright; Lena Li; Maxim N Artyomov; Sanghyun Lee; Megan T Baldridge; Timothy J Nice
Journal:  Elife       Date:  2022-02-09       Impact factor: 8.140

Review 6.  Commensal bacteria in the upper respiratory tract regulate susceptibility to infection.

Authors:  Sarah E Clark
Journal:  Curr Opin Immunol       Date:  2020-05-19       Impact factor: 7.486

7.  The human gut microbiome and health inequities.

Authors:  Katherine R Amato; Marie-Claire Arrieta; Meghan B Azad; Michael T Bailey; Josiane L Broussard; Carlijn E Bruggeling; Erika C Claud; Elizabeth K Costello; Emily R Davenport; Bas E Dutilh; Holly A Swain Ewald; Paul Ewald; Erin C Hanlon; Wrenetha Julion; Ali Keshavarzian; Corinne F Maurice; Gregory E Miller; Geoffrey A Preidis; Laure Segurel; Burton Singer; Sathish Subramanian; Liping Zhao; Christopher W Kuzawa
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-22       Impact factor: 11.205

Review 8.  Post-acute COVID-19 syndrome.

Authors:  Ani Nalbandian; Kartik Sehgal; Aakriti Gupta; Mahesh V Madhavan; Claire McGroder; Jacob S Stevens; Joshua R Cook; Anna S Nordvig; Daniel Shalev; Tejasav S Sehrawat; Neha Ahluwalia; Behnood Bikdeli; Donald Dietz; Caroline Der-Nigoghossian; Nadia Liyanage-Don; Gregg F Rosner; Elana J Bernstein; Sumit Mohan; Akinpelumi A Beckley; David S Seres; Toni K Choueiri; Nir Uriel; John C Ausiello; Domenico Accili; Daniel E Freedberg; Matthew Baldwin; Allan Schwartz; Daniel Brodie; Christine Kim Garcia; Mitchell S V Elkind; Jean M Connors; John P Bilezikian; Donald W Landry; Elaine Y Wan
Journal:  Nat Med       Date:  2021-03-22       Impact factor: 53.440

Review 9.  Short-Chain Fatty Acids as a Potential Treatment for Infections: a Closer Look at the Lungs.

Authors:  Marina Gomes Machado; Valentin Sencio; François Trottein
Journal:  Infect Immun       Date:  2021-08-16       Impact factor: 3.441

Review 10.  Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease.

Authors:  Eileen Haring; Robert Zeiser; Petya Apostolova
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.